- Home
- JANX vs CHI Comparison
JANX vs CHI Comparison
Compare JANX & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JANX | CHI |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 847.1M | 1.0B |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | JANX | CHI |
|---|---|---|
| Price | $14.58 | $12.77 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $47.00 | N/A |
| AVG Volume (30 Days) | ★ 877.9K | 165.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $10.00 |
| 52 Week High | $35.34 | $12.75 |
Technical Indicators
Market Signals| Indicator | JANX | CHI |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 65.21 |
| Support Level | $13.15 | $10.84 |
| Resistance Level | $15.49 | N/A |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 80.14 | 96.56 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.